Key Details
Price
$85.26Annual ROE
-32.43%Beta
0.59Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on developing advanced vaccines to combat bacterial diseases, has announced that its management will take part in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York. This event is scheduled for Thursday, February 6, 2025, at 9:30 a.m. ET / 6:30 a.m. PT.
On January 30, 2025, Kuehn Law, PLLC, a law firm focused on shareholder litigation, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) violated their responsibilities to shareholders. The investigation is focused on possible self-dealing actions. Shareholders might be eligible for compensation and changes in corporate governance.
We have put together a list of the 10 Best Russell 2000 Stocks to Invest in Based on Analyst Recommendations. In this article, we will examine how Vaxcyte, Inc. (NASDAQ:PCVX) compares to other top Russell 2000 stocks recommended by analysts. The Russell 2000 Index is a popular benchmark that...
Since August 2023, Vaxcyte's stock has increased by 68% due to advancements in its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, which targets 95.6% of serotypes, has been chosen for Phase 3 trials, with results anticipated in 2026. The company also has a strong financial standing, with more than $3 billion in cash and investments, allowing for strategic flexibility and longer timelines.
On January 7, 2025, Kuehn Law, PLLC, a law firm focused on shareholder litigation, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) violated their responsibilities to shareholders. The investigation is focused on possible self-dealing actions.
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a law firm focused on shareholder lawsuits, is looking into whether some officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) failed to fulfill their responsibilities to shareholders. The inquiry is related to possible self-dealing actions. Shareholders might be eligible for compensation and changes in corporate governance.
Carillon Tower Advisers, an investment management firm, published its third quarter 2024 investor letter for the "Carillon Eagle Small Cap Growth Fund." You can download the letter here. After facing losses in the second quarter, small-cap stocks saw a significant rise in the third quarter, with the Russell 2000 Growth Index increasing by 8.41%, although it still lagged behind the Russell 2000 Value Index.
The FDA has approved the Investigational New Drug Application for VAX-31 for infants, and the company aims to start the Phase 2 study by the end of January 2025. For adults, the FDA has given Breakthrough Therapy Designation to VAX-31, and the company intends to begin the Phase 3 pivotal study by mid-2025.
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on developing advanced vaccines to combat bacterial diseases, has announced that its management will take part in a fireside chat at the 2024 Cantor Global Healthcare Conference. This event is scheduled for Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Vaxcyte's XpressCF platform allows for the creation of vaccines that can target a wide range of diseases, addressing the challenges of older cell-based methods. The company's main products, VAX-31 and VAX-24, focus on invasive pneumococcal disease (IPD) and offer better protection than other options available. The early results for VAX-31 showed it is safe and effective, setting it up for further testing in Phase 3 trials by mid-2025.
FAQ
- What is the primary business of Vaxcyte?
- What is the ticker symbol for Vaxcyte?
- Does Vaxcyte pay dividends?
- What sector is Vaxcyte in?
- What industry is Vaxcyte in?
- What country is Vaxcyte based in?
- When did Vaxcyte go public?
- Is Vaxcyte in the S&P 500?
- Is Vaxcyte in the NASDAQ 100?
- Is Vaxcyte in the Dow Jones?
- When was Vaxcyte's last earnings report?
- When does Vaxcyte report earnings?
- Should I buy Vaxcyte stock now?